Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 21437020 approvals

CAREGEN CO.,LTD.

Official website

CAREGEN develops peptide-based cosmeceuticals sold in 130 countries and ophthalmic drug candidates CG-P5 and CG-T1.

As of 2026-10-10, CAREGEN CO.,LTD. has 20 Korean MFDS device approvals, 7 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

CAREGEN was founded in 2001 and listed on KOSDAQ in 2015 as a biotech company specializing in new drug development. Built on peptide and growth factor research, it produces professional therapy products such as fillers and mesotherapy items along with functional cosmetics, while developing a pipeline that includes the wet age-related macular degeneration candidate CG-P5 and the dry eye disease candidate CG-T1. The company has built a peptide library backed by more than 860 patents registered at home and abroad, sells its therapy products and functional cosmetics in 130 countries worldwide, and has completed a Phase 1 clinical trial for CG-P5 in the United States with Phase 2 in preparation.

Products & technology

  • Professional therapy products (fillers, mesotherapy)Peptide- and growth-factor-based aesthetic treatment products
  • Functional cosmeticsPeptide- and growth-factor-based cosmetics
  • Blood-glucose-control functional health foodBlood glucose control
  • Muscle-loss prevention and strengthening functional health foodMuscle loss prevention and strengthening

Regulatory approvals

data.go.kr

20 Korean MFDS device approvals · 2011–2023

  • MFDSGraft/prosthesis, biomaterial2023-10-26
    Product approval · Class 4제허 23-1012 호
  • MFDSGraft/prosthesis, biomaterialRevoked2020-07-13
    Product approval · Class 4제허 20-561 호
  • MFDSGraft/prosthesis, biomaterialRevoked2020-07-09
    Product approval · Class 4제허 20-551 호
  • MFDSGraft/prosthesis, biomaterial2020-04-08
    Product approval · Class 4제허 20-265 호
  • MFDSGraft/prosthesis, biomaterial2017-09-14
    Product approval · Class 4제허 17-710 호
  • MFDSGraft/prosthesis, biomaterial2017-09-14
    Product approval · Class 4제허 17-709 호
  • MFDSGraft/prosthesis, biomaterial2017-09-14
    Product approval · Class 4제허 17-708 호
  • MFDSGraft/prosthesis, biomaterial2016-04-28
    Product approval · Class 4제허 16-333 호
  • MFDSGraft/prosthesis, biomaterial2016-04-08
    Product approval · Class 4제허 16-277 호
  • MFDSGraft/prosthesis, biomaterial2016-03-10
    Product approval · Class 4제허 16-179 호
  • MFDSGraft/prosthesis, biomaterialRevoked2015-11-03
    Product approval · Class 4제허 15-1544 호
  • MFDSGraft/prosthesis, biomaterialRevoked2015-11-03
    Product approval · Class 4제허 15-1543 호
Show 8 more
  • MFDSGraft/prosthesis, biomaterial2015-08-10
    Product approval · Class 4제허 15-1294 호
  • MFDSGraft/prosthesis, biomaterialRevoked2015-04-30
    Product approval · Class 4제허 15-660 호
  • MFDSGraft/prosthesis, biomaterial2014-08-27
    Product approval · Class 4제허 14-1570 호
  • MFDSGraft/prosthesis, biomaterial2014-08-27
    Product approval · Class 4제허 14-1569 호
  • MFDSGraft/prosthesis, biomaterial2012-03-05
    Product approval · Class 4제허 12-282 호
  • MFDSGraft/prosthesis, biomaterialRevoked2011-12-08
    Product approval · Class 4제허 11-1343 호
  • MFDSGraft/prosthesis, biomaterialRevoked2011-12-08
    Product approval · Class 4제허 11-1344 호
  • MFDSNasal splint, externalRevoked2011-11-24
    Product approval · Class 1경인 제신 11-339 호

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

CG-P5 · 습성 황반변성(wet AMD) · 임상 1상 완료, 임상 2상 준비중 · Peptide-based eye-drop candidate modulating the VEGF receptor pathway; Phase 1 results announced in the US in December 2025 showed signals related to reduced intraretinal fluid.

CG-T1 · 안구건조증 · 전임상 시험 진행중 · Peptide-based eye-drop candidate targeting the PAC1 receptor; preclinical studies showed efficacy signals such as increased tear secretion, with a clinical development strategy for FDA submission in preparation.

건성황반변성 치료제 · 건성황반변성 · 전임상시험 완료 · Eye-drop candidate that inhibits drusen formation via antioxidant activity and neovascularization suppression.

당뇨병성 망막병증 치료제 · 당뇨병성 망막병증 · 전임상시험 완료 · Inhibits VEGF receptor function to suppress neovascularization and vascular dilation.

다한증 치료제 · 다한증 · 인체적용시험 완료 · Early-stage program; mechanism and details undisclosed.

항바이러스 치료제 · COVID-19 · 임상 1상 완료 · Binds the SARS-CoV-2 spike protein to inhibit cell entry and improves symptoms via an anti-inflammatory effect.

근육강화 소재 · 근육 강화(노인성 근감소 개선) · 인체적용시험 완료, 2025년 2월 FDA NDI 허가 승인 · Health-functional-food ingredient promoting muscle fiber differentiation and regeneration.

혈당·비알콜성 지방간 개선 소재 · 혈당 감소, 비알콜성 지방간 · 인체적용시험 완료 · Ingredient reducing blood glucose via decreased insulin resistance and increased sensitivity; combination trials with metformin and ProGsterol ongoing.

고지혈증 개선 소재 · 콜레스테롤 감소 · 인체적용시험 완료 · Ingredient reducing cholesterol via inhibition of hepatic lipid synthesis and production.

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 363 more patents

AI reads

MAA server logs · IP-verified
95
Times AI engines pulled CAREGEN CO.,LTD.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

3
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

92
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

10
live 0
Last 7 days
78
live 2
Last 30 days
95
live 3
All time
  • OpenAIChatGPT-Userlive3
  • OpenAIOAI-SearchBot79
  • GoogleGoogleOther7
  • PerplexityPerplexityBot3
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for CAREGEN CO.,LTD. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Humedix Co., Ltd.3 shared

KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.

HANS BIOMED CORPORATION2 shared

KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.

BioPlus Co., Ltd2 shared

Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.

HUONS CO., LTD.2 shared

KOSDAQ-listed pharmaceutical and healthcare company producing lidocaine anesthetics and the Kynix hyaluronic-acid eye-drop line.

DongBang Medical Co., Ltd.2 shared

KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.

BIOBIJOU Co., Ltd.2 shared

KOSDAQ-listed aesthetics exporter behind HA skin booster CANDOLOV SERUM and filler brands COLENA and CANDORLOV.

Chabiotech Co.,Ltd.2 shared

Cord blood storage and cell therapy company that has expanded into global CDMO manufacturing and overseas medical network services.

DAE HWA PHARM CO., LTD2 shared

KOSDAQ-listed pharmaceutical company behind the world's first oral paclitaxel Liporaxel (DHP107) and the Amalian dermal filler.

JETEMA Co.,Ltd.2 shared

Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.

PharmaResearch Co., Ltd.2 shared

KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.

BNC KOREA, Inc.2 shared

Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.

DongKookPharmaceuticalCo.,Ltd.2 shared

KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition